Abstract
Many relatively effective strategies for treatment of nearly all forms of chemosensitive cancer include combinations or alternations of agents that are supposed to have different modes of actions. In part these strategies are based on the assumption that such differing modes of action will ensure that tumor cells that are not sensitive to one agent will react to the other. This assumption requires that a close relation exists between mode of action of a drug and the mechanism of resistance operating for that drug in tumor cells. We have studied this hypothesis for two drugs that are considered to be active cytotoxic agents in a number of human malignancies, including small cell lung cancer, namely Adriamycin (ADR) and CDDP. This preliminary report concerns some details on the pheno- and genotype, and resistance mechanisms of a platinum (GLC4-CDDP) and of an ADR resistant (GLC4-ADR) and a CDDP resistant (GLC4-CDDP) cell line, both derived from a sensitive human small cell lung cancer cell line (GLC4).
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
